Clinical

A phase 3, randomized, double-blind registration study in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy has found clinical equivalence between filgrastim and its biosimilar after switching studies.

A poster discussion session at the 2017 Annual Meeting of the American Society of Clinical Oncology examined retrospective surveillance data in 3 different cancers: non-small cell lung cancer, head and neck cancer, and colorectal cancer.

One of the kickoff sessions on the first day of the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, was a lively discussion on ensuring that the data used to inform patient care and create healthcare policies holds value.

A late afternoon extended education session on the first day of the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, was a discussion on the state-of-the-art uses for immunotherapy in the management of non-small cell lung cancer (NSCLC).

Checkpoint inhibitors have begun to revolutionize bladder cancer treatments, but the benefits in prostate cancer are a little less clear at this point, explained Daniel George, MD, of the Duke Cancer Insitute.

Patients with cystic fibrosis face a lifetime of time-consuming treatment. There are new breakthrough therapies that not only treat symptoms of the disease, but also the underlying causes, which represents a source of hope for patients. However, barriers to treatment still stand in the way, according to a new white paper from the Cystic Fibrosis Engagement Network.

Analysis of data available within a national hospital-based registry showed that the diagnosis of stage I disease increased for female breast cancer, colorectal cancer, and lung cancer following implementation of the Affordable Care Act (ACA).

The National Heart, Lung, and Blood Institute has released the first-ever COPD National Action Plan, which is aimed at ending the illness.

According to the study, to be presented at the 2017 American Society of Clinical Oncology Annual Meeting, vaccination resulted in an 88% overall reduction in vaccine-type infections and a 100% reduction among men, in the young adult population.

Patients with metastatic non-small cell lung cancer (NSCLC) who have a rearrangement in the anaplastic lymphoma kinase (ALK) gene now have a first-line option: ceritinib.